Compare · EW vs HSCS
EW vs HSCS
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and HeartSciences Inc. (HSCS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and HSCS operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $49.79B, about 9361.6x HSCS ($5.3M).
- Over the past year, EW is up 10.8% and HSCS is down 53.9% - EW leads by 64.8 points.
- EW has been more active in the news (13 items in the past 4 weeks vs 1 for HSCS).
- EW has more recent analyst coverage (25 ratings vs 0 for HSCS).
- Company
- Edwards Lifesciences Corporation
- HeartSciences Inc.
- Price
- $86.49+0.62%
- $1.70-4.49%
- Market cap
- $49.79B
- $5.3M
- 1M return
- +6.49%
- -18.27%
- 1Y return
- +10.83%
- -53.93%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 13
- 1
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest EW
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
- CEO Zovighian Bernard J converted options into 47,207 shares, covered exercise/tax liability with 26,198 shares, gifted 26,640 shares, received a gift of 26,640 shares and sold $2,833,013 worth of shares (36,351 units at $77.93) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 99,165 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr converted options into 13,457 shares and covered exercise/tax liability with 7,469 shares, increasing direct ownership by 22% to 32,766 units (SEC Form 4)
- CVP, TMTT & Surgical Chopra Daveen converted options into 13,583 shares and covered exercise/tax liability with 7,538 shares, increasing direct ownership by 15% to 45,824 units (SEC Form 4)
- CVP, Chief Financial Officer Ullem Scott B. covered exercise/tax liability with 11,004 shares and converted options into 19,830 shares, increasing direct ownership by 23% to 46,740 units (SEC Form 4)
Latest HSCS
- HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
- HeartSciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
- SEC Form QUALIF filed by HeartSciences Inc.
- SEC Form 253G2 filed by HeartSciences Inc.
- HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
- SEC Form 1-A POS filed by HeartSciences Inc.
- HeartSciences Inc. filed SEC Form 8-K: Leadership Update
- HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
- HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings